Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030

Overview

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2019, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years, across the globe. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, are still considered as the current standard of care. However, their efficacy is severely limited, especially when it comes to treating late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, are known to have a significant adverse impact on patients’ quality of life.

There are several targeted anti-cancer therapies that are available in the market and many are presently under development. Of these, immune checkpoint therapies have shown a lot of promise as viable and potent treatment options, capable of preventing tumor cells from evading immune surveillance. In 2011, Bristol-Myers Squibb’s Yervoy® (ipilimumab), an anti-CTLA-4 monoclonal antibody, became the first FDA approved immune checkpoint inhibitor which was designed for the treatment of metastatic melanoma. Yervoy®, along with other first generation immune checkpoint inhibitors (targeting PD-1/PD-L1 and CTLA-4), soon demonstrated the ability to substantially prolong the lives of patients suffering from advanced stage tumors. However, despite the success of PD 1/PD-L1 inhibitor drugs, there was a notable amount of resistance to treatment reported in certain groups of patients, which compromised the therapeutic potential of this relatively novel class of therapeutics.

Over the years, significant strides have been made in immune checkpoint modulation research, revealing several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are now being exploited for development of next generation immune checkpoint-based therapies. Moreover, clinical studies of combinatorial immune checkpoint blockade/co-stimulation, involving the newly identified checkpoints and known immune checkpoint inhibitor therapies, have demonstrated the potential to further augment therapeutic benefits. It is worth highlighting that these molecules have also shown to be capable of regulating immune tolerance and preventing/treating autoimmune disorders. Therefore, backed by promising clinical results and expanding applicability of therapies being investigated in late stages of development, the immune checkpoint inhibitors and stimulators market is poised to witness substantial growth in the foreseen future.

Scope of the Report

The “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

In addition to other elements, the study includes:

A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical/discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).
A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors/collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.
Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoints and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as grant amount, support period, type of grant application and number of disease indications under investigation.
An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals.
An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.
An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for next generation immune checkpoint inhibitors and stimulators, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of next generation checkpoint modulator therapies and their likely selling price, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (colorectal cancer, head and neck cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, primary Sjögren's syndrome and systemic lupus erythematosus/lupus nephritis) [B] key immune checkpoint targets (B7-H3, CD38, CD40, CD47 and ICOS [C] mechanisms of action (inhibitory and costimulatory), [D] therapeutic modalities used (antibody fragment, monoclonal antibody and small molecule), [E] type of therapy (monotherapy, combination therapy and both), [F] route of administration (intravenous, subcutaneous and intracerebroventricular) and [G] key geographical regions (US, EU5, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy
3.4. Immune Checkpoint Modulators
3.5. First Generation Immune Checkpoint Modulators
3.6. Next Generation Immune Checkpoint Modulators
3.6. 1.Types of Next Generation Immune Checkpoint Modulators
3.7. Challenges-related to Immune Checkpoint Modulation-based Therapy
3.8. Future Perspectives

4. CURRENT MARKET LANDSCAPE: CLINICAL AND PRECLINICAL MOLECULES

4.1. Chapter Overview
4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
4.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Immune Checkpoint
4.3.3. Analysis by Mechanism of Action
4.3.4. Analysis by Therapeutic Modality
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Therapeutic Area
4.3.8. Analysis by Type of Therapy
4.3.9. Funnel Representation: Analysis by Phase of Development, Mechanism of Action and Type of Therapy
4.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developer Companies: Analysis by Number of Pipeline Therapies
4.4.4. World Map Representation: Analysis by Geography

5. MARKET LANDSCAPE: THERAPIES TARGETING CD47

5.1. Chapter Overview
5.2. Next Generation Immune Checkpoint Inhibitors: Development Pipeline of CD47 Targeting Therapies
5.3. Next Generation Immune Checkpoint Inhibitors: Pipeline Analysis of CD47 Targeting Therapies
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Therapeutic Modality
5.3.3. Analysis by Route of Administration
5.3.4. Analysis by Target Disease Indication
5.3.5. Analysis by Type of Therapy
5.4. Next Generation Immune Checkpoint Inhibitors: List of Companies Developing CD47 Targeting Therapies
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size and Geographical Location
5.4.3. Leading Developers: Analysis by Number of Therapies
5.4.4. World Map Representation: Analysis by Geography

6. MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB

6.1. Chapter Overview
6.2. Next Generation Immune Checkpoint Stimulators: Development Pipeline of 4-1BB Targeting Therapies
6.3. Next Generation Immune Checkpoint Stimulators: Pipeline Analysis of 4-1BB Targeting Therapies
6.3.1. Analysis by Phase of Development
6.3.2. Analysis by Therapeutic Modality
6.3.3. Analysis by Route of Administration
6.3.4. Analysis by Target Disease Indication
6.3.5. Analysis by Type of Therapy
6.4. Next Generation Immune Checkpoint Stimulators: List of Companies Developing 4-1BB Targeting Therapies
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Company Size and Geographical Location
6.4.3. Leading Developers: Analysis by Number of Therapies
6.4.4. World Map Representation: Analysis by Geography

7. CLINICAL TRIAL ANALYSIS

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
7.3.8. Word Cloud: Key Focus Areas
7.3.9. Analysis by Target Immune Checkpoint
7.3.10. Analysis by Target Therapeutic Area
7.3.11. Popular Interventions: Analysis by Number of Registered Trials
7.3.12. Geographical Analysis by Number of Registered Trials
7.3.13. Geographical Analysis by Trial Recruitment Status
7.3.14. Geographical Analysis by Number of Patients Enrolled

8. COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS

8.1. Chapter Overview
8.2. Bristol-Myers Squibb
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. Eli Lilly
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. GlaxoSmithKline
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook
8.4. Novartis
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. XOMA
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.5.4. Recent Developments and Future Outlook

9. ACADEMIC GRANTS ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)
9.3.1. Analysis by Year of Grant Award
9.3.2. Analysis by Amount Awarded
9.3.3. Analysis by Administering Institute Center
9.3.4. Analysis by Funding Institute Center
9.3.5. Analysis by Support Period
9.3.6. Analysis by Funding Institute Center and Support Period
9.3.7. Analysis by Type of Grant Application
9.3.8. Analysis by Purpose of Grant Award
9.3.9. Analysis by Grant Mechanism
9.3.10. Word Cloud: Emerging Focus Areas
9.3.11. Popular Target Immune Checkpoints: Analysis by Number of Grants
9.3.12. Analysis of Grant Amount Awarded by Target Immune Checkpoints
9.3.13. Analysis by Study Section Involved
9.3.14. Analysis by Types of Recipient Organizations
9.3.15. Popular Recipient Organizations: Analysis by Number of Grants
9.3.16. Prominent Program Officers: Analysis by Number of Grants
9.3.17. Regional Analysis of Recipient Organizations
9.4. Grant Attractiveness Analysis

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Target Immune Checkpoint
10.3.4. Analysis by Year of Partnership and Target Immune Checkpoint
10.3.5. Analysis by Type of Partnership and Target Immune Checkpoint
10.3.6. Analysis by Type of Partnership and Target Disease Indication
10.3.7. Analysis by Year and Type of Partner
10.3.8. Most Active Players: Analysis by Number of Partnerships
10.3.9. Regional Analysis
10.3.10. Intercontinental and Intracontinental Agreements

11. TARGET COMPETITIVENESS ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors and Stimulators
11.3.1. Four-Dimensional Bubble Analysis
11.3.2 Five-Dimensional Spider Web Analysis

12. BIG PHARMA INITIATIVES

12.1. Chapter Overview
12.2. Big Pharma Initiatives Focused on Next Generation Immune Checkpoint
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Product Development Strategy
12.2.4. Analysis by Target Immune Checkpoint Modulators
12.2.5. Grid Representation: Analysis by Product Development Strategy and Target Immune Checkpoint
12.2.6. Analysis by Therapeutic Area
12.2.6.1. Heat Map: Big Pharma Initiatives Focused on Oncological Indications
12.2.6.2. Heat Map: Big Pharma Initiatives Focused on Non-Oncological Indications

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030
13.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Individual Product Sales Forecasts
13.4.1. DARZALEX® (Janssen Pharmaceuticals)
13.4.1.1. Target Patient Population
13.4.1.2. Sales Forecast
13.4.2. GSK3359609 (GlaxoSmithKline)
13.4.2.1. Target Patient Population
13.4.2.2. Sales Forecast
13.4.3. RRx-001 (EpicentRx)
13.4.3.1. Target Patient Population
13.4.3.2. Sales Forecast
13.4.4. SAR650984 (Sanofi)
13.4.4.1. Target Patient Population
13.4.4.2. Sales Forecast
13.4.5. MGA271 (MacroGenics)
13.4.5.1. Target Patient Population
13.4.5.2. Sales Forecast
13.4.6. Omburtamab (Y-mAbs Therapeutics)
13.4.6.1. Target Patient Population
13.4.6.2. Sales Forecast
13.4.7. AMG557 (Amgen)
13.4.7.1. Target Patient Population
13.4.7.2. Sales Forecast
13.4.8. APX005M (Apogenix)
13.4.8.1. Target Patient Population
13.4.8.2. Sales Forecast
13.4.9. BI 655064 (Boehringer Ingelheim)
13.4.9.1. Target Patient Population
13.4.9.2. Sales Forecast
13.4.10. Dapirolizumab Pegol (UCB Pharma)
13.4.10.1. Target Patient Population
13.4.10.2. Sales Forecast
13.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region
13.5.1. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020-2030
13.5.2. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Europe, 2020-2030
13.5.3. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Asia-Pacific, 2020-2030
13.5.4. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Rest of the World, 2020-2030
13.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication
13.6.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2020-2030
13.6.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2020-2030
13.6.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Hematological Malignancies, 2020-2030
13.6.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2020-2030
13.6.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2020-2030
13.6.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2020-2030
13.6.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-Oncological Indications, 2020-2030
13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint
13.7.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2020-2030
13.7.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030
13.7.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2020-2030
13.7.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2020-2030
13.7.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2020-2030
13.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action
13.8.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030
13.8.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2020-2030
13.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality
13.9.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Antibody Fragments, 2020-2030
13.9.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibodies, 2020-2030
13.9.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, 2020-2030
13.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy
13.10.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030
13.10.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030
13.10.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2020-2030
13.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration
13.11.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2020-2030
13.11.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030
13.11.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2020-2030

14. CONCLUDING REMARKS15. EXECUTIVE INSIGHTS16. APPENDIX 1: TABULATED DATA

List Of Figures

Figure 3.1 Mechanisms of Action of Immunotherapies
Figure 3.2 Types of Immune Checkpoint Targets
Figure 4.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Phase of Development
Figure 4.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Immune Checkpoint
Figure 4.3 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Mechanism of Action
Figure 4.4 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Modality
Figure 4.5 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Route of Administration
Figure 4.6 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Disease Indication
Figure 4.7 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Area
Figure 4.8 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Type of Therapy
Figure 4.9 Funnel Representation: Distribution by Phase of Development, Mechanism of Action and Type of Therapy
Figure 4.10 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Year of Establishment
Figure 4.11 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Company Size and Geographical Location
Figure 4.12 Leading Developer Companies: Distribution by Number of Pipeline Therapies
Figure 4.13 World Map Representation: Distribution by Geography
Figure 5.1 Immune Checkpoint Inhibitors for CD47: Distribution by Phase of Development
Figure 5.2 Immune Checkpoint Inhibitors for CD47: Distribution by Therapeutic Modality
Figure 5.3 Immune Checkpoint Inhibitors for CD47: Distribution by Route of Administration
Figure 5.4 Immune Checkpoint Inhibitors for CD47: Distribution by Target Disease Indication
Figure 5.5 Immune Checkpoint Inhibitors for CD47: Distribution by Type of Therapy
Figure 5.6 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Year of Establishment
Figure 5.7 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Company Size and Geographical Location
Figure 5.8 Leading Developers: Distribution by Number of Pipeline Therapies for CD47
Figure 5.8 World Map Representation: Distribution by Geography
Figure 6.1 Immune Checkpoint Stimulators for 4-1BB: Distribution by Phase of Development
Figure 6.2 Immune Checkpoint Stimulators for 4-1BB: Distribution by Therapeutic Modality
Figure 6.3 Immune Checkpoint Stimulators for 4-1BB: Distribution by Route of Administration
Figure 6.4 Immune Checkpoint Stimulators for 4-1BB: Distribution by Target Disease Indication
Figure 6.5 Immune Checkpoint Stimulators for 4-1BB: Distribution by Type of Therapy
Figure 6.6 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Year of Establishment
Figure 6.7 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Company Size and Geographical Location
Figure 6.8 Leading Developers: Distribution by Number of Therapies for 4-1BB
Figure 6.9 World Map Representation: Distribution by Geography
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
Figure 7.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.8 Leading Industry Sponsors: Distribution by Number of Registered Trials
Figure 7.9 Word Cloud: Key Focus Areas
Figure 7.10 Clinical Trial Analysis: Distribution by Target Immune Checkpoint
Figure 7.11 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 7.12 Popular Interventions: Distribution by Number of Registered Trials
Figure 7.13 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 7.14 Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Figure 7.15 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 8.1 Bristol-Myers Squibb: Annual Revenues, 2014- 9M 2019 (USD Billion)
Figure 8.2 Eli Lilly: Annual Revenues, 2014- 3M 2019 (USD Billion)
Figure 8.3 GlaxoSmithKline: Annual Revenues, 2014-2019 (USD Billion)
Figure 8.4 Novartis: Annual Revenues, 2014-6M 2019 (USD Billion)
Figure 8.5 XOMA: Annual Revenues, 2014-9M 2019 (USD Million)
Figure 9.1 Grant Analysis: Distribution by Year of Grant Award, 2016-2019
Figure 9.2 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2019
Figure 9.3 Grant Analysis: Distribution by Administering Institute Center
Figure 9.4 Grant Analysis: Distribution by Funding Institute Center
Figure 9.5 Grant Analysis: Distribution by Support Period
Figure 9.6 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 9.7 Grant Analysis: Distribution by Type of Grant Application
Figure 9.8 Grant Analysis: Distribution by Purpose of Grant Award
Figure 9.9 Grant Analysis: Distribution by Grant Mechanism
Figure 9.10 Word Cloud: Emerging Focus Areas
Figure 9.11 Popular Target Immune Checkpoints: Distribution by Number of Grants
Figure 9.12 Grant Analysis: Distribution of Grant Amount Awarded by Target Immune Checkpoints
Figure 9.13 Grant Analysis: Distribution by Study Section Involved
Figure 9.14 Grant Analysis: Distribution by Types of Recipient Organizations
Figure 9.15 Popular Recipient Organizations: Distribution by Number of Grants
Figure 9.16 Prominent Program Officers: Distribution by Number of Grants
Figure 9.17 Grant Analysis: Distribution by Recipient Organizations
Figure 9.18 Grant Analysis: Categorizations based on Weighted Attractiveness Scores
Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2020.
Figure 10.4. Partnerships and Collaborations: Distribution by Target Immune Checkpoint
Figure 10.5. Partnerships and Collaborations: Distribution by Year of Partnership and Target Immune Checkpoint
Figure 10.6. Partnerships and Collaborations: Distribution Type of Partnership and Target Immune Checkpoint
Figure 10.7. Partnerships and Collaborations: Distribution by Type of Partnership and Target Disease Indication
Figure 10.8. Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 10.9. Most Active Players: Distribution by Number of Partnerships
Figure 10.10. Partnership and Collaborations: Regional Distribution
Figure 10.11. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 11.1. Target Competitiveness Analysis: Four-Dimensional Bubble Analysis
Figure 11.2. Target Competitiveness Analysis: Five-Dimensional Spider Web Analysis
Figure 12.1. Big Pharma Initiatives: Distribution by Number of Initiatives
Figure 12.2. Big Pharma Initiatives: Distribution by Product Development Strategy
Figure 12.3. Big Pharma Initiatives: Distribution by Target Immune Checkpoint
Figure 12.4. Grid Representation: Distribution by Product Development Strategy and Target Immune Checkpoint
Figure 12.5. Big Pharma Initiatives: Distribution by Therapeutic Area
Figure 12.6. Heat Map: Big Pharma Initiatives Focused on Oncological Indications
Figure 12.7. Heat Map: Big Pharma Initiatives Focused on Non-Oncological Indications
Figure 13.1 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 (USD Million)
Figure 13.2 DARZALEX®: Target Patient Population
Figure 13.3 DARZALEX®: Sales Forecast
Figure 13.4 GSK3359609: Target Patient Population
Figure 13.5 GSK3359609: Sales Forecast
Figure 13.6 RRx-001: Target Patient Population
Figure 13.7 RRx-001: Sales Forecast
Figure 13.8 SAR650984: Target Patient Population
Figure 13.9 SAR650984: Sales Forecast
Figure 13.10 MGA271: Target Patient Population
Figure 13.11 MGA271: Sales Forecast
Figure 13.12 Omburtamab: Target Patient Population
Figure 13.13 Omburtamab: Sales Forecast
Figure 13.14 AMG557: Target Patient Population
Figure 13.15 AMG557: Sales Forecast
Figure 13.16 APX005M: Target Patient Population
Figure 13.17 APX005M: Sales Forecast
Figure 13.18 BI 655064: Target Patient Population
Figure 13.19 BI 655064: Sales Forecast
Figure 13.20 Dapirolizumab Pegol: Target Patient Population
Figure 13.21 Dapirolizumab Pegol: Sales Forecast
Figure 13.22 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region (USD Million)
Figure 13.23 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020-2030 (USD Million)
Figure 13.24 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Europe, 2020-2030 (USD Million)
Figure 13.25 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 13.26 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Rest of the World, 2020-2030 (USD Million)
Figure 13.27 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication (USD Million)
Figure 13.28 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2020-2030 (USD Million)
Figure 13.29 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2020-2030 (USD Million)
Figure 13.30 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Hematological Malignancies, 2020-2030 (USD Million)
Figure 13.31 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2020-2030 (USD Million)
Figure 13.32 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2020-2030 (USD Million)
Figure 13.33 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2020-2030 (USD Million)
Figure 13.34 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-Oncological Indications, 2020-2030 (USD Million)
Figure 13.35 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint (USD Million)
Figure 13.36 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2020-2030 (USD Million)
Figure 13.37 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030 (USD Million)
Figure 13.38 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2020-2030 (USD Million)
Figure 13.39 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2020-2030 (USD Million)
Figure 13.40 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2020-2030 (USD Million)
Figure 13.41 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action (USD Million)
Figure 13.42 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030 (USD Million)
Figure 13.43 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2020-2030 (USD Million)
Figure 13.44 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality (USD Million)
Figure 13.45 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Antibody Fragments, 2020-2030 (USD Million)
Figure 13.46 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibodies, 2020-2030 (USD Million)
Figure 13.47 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, 2020-2030 (USD Million)
Figure 13.48 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy (USD Million)
Figure 13.49 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030 (USD Million)
Figure 13.50 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030 (USD Million)
Figure 13.51 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2020-2030 (USD Million)
Figure 13.52 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration (USD Million)
Figure 13.53 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2020-2030 (USD Million)
Figure 13.54 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030 (USD Million)
Figure 13.55 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2020-2030 (USD Million)

List Of Tables

Table 3.1 Types of Immunotherapies and Associated Mechanisms of Action
Table 4.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
Table 4.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
Table 5.1 Immune Checkpoint Inhibitors for CD47: Development Pipeline
Table 5.2 Immune Checkpoint Inhibitors for CD47: List of Therapy Developers
Table 6.1 Immune Checkpoint Stimulators for 4-1BB: Development Pipeline
Table 6.2 Immune Checkpoint Stimulators: List of Therapy Developers
Table 8.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Companies Profiled
Table 8.2 Bristol- Myers Squibb: Company Snapshot
Table 8.3 Drug Profile: BMS-986016
Table 8.4 Drug Profile: BMS-986015
Table 8.5 Drug Profile: BMS-986213
Table 8.6 Drug Profile: BMS-986156
Table 8.7 Drug Profile: BMS-986207
Table 8.8 Drug Profile: BMS-986179
Table 8.9 Drug Profile: BMS-986258
Table 8.10 Drug Profile: BMS-663513
Table 8.11 Drug Profile: BMS-986205
Table 8.12 Drug Profile: BMS-986178
Table 8.13 Drug Profile: BMS-936561
Table 8.14 Recent Developments and Future Outlook
Table 8.15 Eli Lilly: Company Snapshot
Table 8.16 Drug Profile: LY3321367
Table 8.17 Drug Profile: LY3415244
Table 8.18 Drug Profile: LY3475070
Table 8.19 Drug Profile: LY3381916
Table 8.20 Drug Profile: BLTA Agonist
Table 8.21 Drug Profile: CD200R Agonist
Table 8.22 Recent Developments and Future Outlook
Table 8.23 GlaxoSmithKline: Company Snapshot
Table 8.24 Drug Profile: GSK3359609
Table 8.25 Drug Profile: GSK2831781
Table 8.26 Drug Profile: GSK3174998
Table 8.27 Drug Profile: TSR-022
Table 8.28 Drug Profile: TSR-033
Table 8.29 Drug Profile: TSR-075
Table 8.30 Recent Developments and Future Outlook
Table 8.31 Novartis: Company Snapshot
Table 8.32 Drug Profile: CDZ173
Table 8.33 Drug Profile: CFZ533
Table 8.34 Drug Profile: MBG453
Table 8.35 Drug Profile: LAG525
Table 8.36 Drug Profile: GWN323
Table 8.37 Drug Profile: NZV930
Table 8.38 Recent Developments and Future Outlook
Table 8.39 XOMA: Company Snapshot
Table 8.40 Drug Profile: PBF-509
Table 8.41 Drug Profile: PBF-677
Table 8.42 Drug Profile: PBF-999
Table 8.43 Recent Developments and Future Outlook
Table 9.1 Grant Analysis: Multivariate Grant Attractiveness Analysis
Table 10.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
Table 13.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Forecasted Drug Candidates
Table 16.1 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Phase of Development
Table 16.2 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Immune Checkpoint
Table 16.3 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Mechanism of Action
Table 16.4 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Modality
Table 16.5 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Route of Administration
Table 16.6 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Target Disease Indication
Table 16.7 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Therapeutic Area
Table 16.8 Next Generation Immune Checkpoint Inhibitors and Stimulators: Distribution by Type of Therapy
Table 16.9 Funnel Representation: Distribution by Phase of Development, Mechanism of Action and Type of Therapy
Table 16.10 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Year of Establishment
Table 16.11 Next Generation Immune Checkpoint Inhibitors and Stimulators Therapy Developers: Distribution by Company Size and Geographical Location
Table 16.12 Leading Developer Companies: Distribution by Number of Pipeline Therapies
Table 16.13 Immune Checkpoint Inhibitors for CD47: Distribution by Phase of Development
Table 16.14 Immune Checkpoint Inhibitors for CD47: Distribution by Therapeutic Modality
Table 16.15 Immune Checkpoint Inhibitors for CD47: Distribution by Route of Administration
Table 16.16 Immune Checkpoint Inhibitors for CD47: Distribution by Target Disease Indication
Table 16.17 Immune Checkpoint Inhibitors for CD47: Distribution by Type of Therapy
Table 16.18 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Year of Establishment
Table 16.19 Immune Checkpoint Inhibitors for CD47 Therapy Developers: Distribution by Company Size and Geographical Location
Table 16.20 Leading Developers: Distribution by Number of Pipeline Therapies for CD47
Table 16.21 Immune Checkpoint Stimulators for 4-1BB: Distribution by Phase of Development
Table 16.22 Immune Checkpoint Stimulators for 4-1BB: Distribution by Therapeutic Modality
Table 16.23 Immune Checkpoint Stimulators for 4-1BB: Distribution by Route of Administration
Table 16.24 Immune Checkpoint Stimulators for 4-1BB: Distribution by Target Disease Indication
Table 16.25 Immune Checkpoint Stimulators for 4-1BB: Distribution by Type of Therapy
Table 16.26 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Year of Establishment
Table 16.27 Immune Checkpoint Stimulators for 4-1BB Therapy Developers: Distribution by Company Size and Geographical Location
Table 16.28 Leading Developers: Distribution by Number of Therapies for 4-1BB
Table 16.29 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
Table 16.30 Clinical Trial Analysis: Distribution by Trial Phase
Table 16.31 Clinical Trial Analysis: Distribution by Trial Status
Table 16.32 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Table 16.33 Clinical Trial Analysis: Distribution by Study Design
Table 16.34 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.35 Leading Industry Sponsors: Distribution by Number of Registered Trials
Table 16.36 Clinical Trial Analysis: Distribution by Target Immune Checkpoint
Table 16.37 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 16.38 Popular Interventions: Distribution by Number of Registered Trials
Table 16.39 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 16.40 Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table 16.41 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 16.42 Bristol-Myers Squibb: Annual Revenues, 2014- 9M 2019 (USD Billion)
Table 16.43 Eli Lilly: Annual Revenues, 2014- 3M 2019 (USD Billion)
Table 16.44 GlaxoSmithKline: Annual Revenues, 2014-2019 (USD Billion)
Table 16.45 Novartis: Annual Revenues, 2014-6M 2019 (USD Billion)
Table 16.46 XOMA: Annual Revenues, 2014-9M 2019 (USD Million)
Table 16.47 Grant Analysis: Distribution by Year of Grant Award, 2016-2019
Table 16.48 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2019
Table 16.49 Grant Analysis: Distribution by Administering Institute Center
Table 16.50 Grant Analysis: Distribution by Funding Institute Center
Table 16.51 Grant Analysis: Distribution by Support Period
Table 16.52 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 16.53 Grant Analysis: Distribution by Type of Grant Application
Table 16.54 Grant Analysis: Distribution by Purpose of Grant Award
Table 16.55 Grant Analysis: Distribution by Grant Mechanism
Table 16.56 Popular Target Immune Checkpoints: Distribution by Number of Grants
Table 16.57 Grant Analysis: Distribution of Grant Amount Awarded by Target Immune Checkpoints
Table 16.58 Grant Analysis: Distribution by Study Section Involved
Table 16.59 Grant Analysis: Distribution by Types of Recipient Organizations
Table 16.60 Popular Recipient Organizations: Distribution by Number of Grants
Table 16.61 Prominent Program Officers: Distribution by Number of Grants
Table 16.62 Grant Analysis: Distribution by Recipient Organizations
Table 16.63 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
Table 16.64 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.65 Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2020.
Table 16.66 Partnerships and Collaborations: Distribution by Target Immune Checkpoint
Table 16.67 Partnerships and Collaborations: Distribution by Year of Partnership and Target Immune Checkpoint
Table 16.68 Partnerships and Collaborations: Distribution Type of Partnership and Target Immune Checkpoint
Table 16.69 Partnerships and Collaborations: Distribution by Type of Partnership and Target Disease Indication
Table 16.70 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 16.71 Most Active Players: Distribution by Number of Partnerships
Table 16.72 Partnership and Collaborations: Regional Distribution
Table 16.73 Big Pharma Initiatives: Distribution by Number of Initiatives
Table 16.74 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 (USD Million)
Table 16.75 DARZALEX®: Sales Forecast
Table 16.76 GSK3359609: Sales Forecast
Table 16.77 RRx-001: Sales Forecast
Table 16.78 SAR650984: Sales Forecast
Table 16.79 MGA271: Sales Forecast
Table 16.80 Omburtamab: Sales Forecast
Table 16.81 AMG557: Sales Forecast
Table 16.82 APX005M: Sales Forecast
Table 16.83 BI 655064: Sales Forecast
Table 16.84 Dapirolizumab Pegol: Sales Forecast
Table 16.85 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region (USD Million)
Table 16.86 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020-2030 (USD Million)
Table 16.87 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Europe, 2020-2030 (USD Million)
Table 16.88 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Asia-Pacific, 2020-2030 (USD Million)
Table 16.89 Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Rest of the World, 2020-2030 (USD Million)
Table 16.90 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication (USD Million)
Table 16.91 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2020-2030 (USD Million)
Table 16.92 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2020-2030 (USD Million)
Table 16.93 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Hematological Malignancies, 2020-2030 (USD Million)
Table 16.94 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2020-2030 (USD Million)
Table 16.95 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2020-2030 (USD Million)
Table 16.96 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2020-2030 (USD Million)
Table 16.97 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-Oncological Indications, 2020-2030 (USD Million)
Table 16.98 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint (USD Million)
Table 16.99 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2020-2030 (USD Million)
Table 16.100 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030 (USD Million)
Table 16.101 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2020-2030 (USD Million)
Table 16.102 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2020-2030 (USD Million)
Table 16.103 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2020-2030 (USD Million)
Table 16.104 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action (USD Million)
Table 16.105 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030 (USD Million)
Table 16.106 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2020-2030 (USD Million)
Table 16.107 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality (USD Million)
Table 16.108 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Antibody Fragments, 2020-2030 (USD Million)
Table 16.109 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibodies, 2020-2030 (USD Million)
Table 16.110 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, 2020-2030 (USD Million)
Table 16.111 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy (USD Million)
Table 16.112 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030 (USD Million)
Table 16.113 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030 (USD Million)
Table 16.114 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2020-2030 (USD Million)
Table 16.115 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration (USD Million)
Table 16.116 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2020-2030 (USD Million)
Table 16.117 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030 (USD Million)
Table 16.118 Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2020-2030 (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie
AbClon
Abeome
ABL Bio
Abpro
Acerta Pharma
Acrus Biosciences
Actinium Pharmaceuticals
Adaptive Biotechnologies
AdoRx Therapeutics
Aduro Biotech
Advaxis
Agenus
Agios Pharmaceuticals
Alexion Pharmaceuticals
Allergan
Alligator Bioscience
Alpine Immune Sciences
ALX Oncology
Amgen
Angel Therapeutics
Anvil Biosciences (The company has been acquired)
Apexigen
Apogenix
Aptevo Therapeutics
Arch Oncology
Arcus Biosciences
ArQule
Astellas Pharma
Astex Pharmaceuticals
AstraZeneca
Atridia
Aurigene Discovery Technologies
Avacta Life Sciences
Bach BioSciences
BeiGene
BinDeBio Group
BIOCAD
Biodextris
BioNTech
Bio-Techne
Black Belt Therapeutics
BliNK Biomedical
bluebird bio
Boehringer Ingelheim
Boston Medical Center
Brigham and Women's Hospital
Bristol-Myers Squibb
Calithera Biosciences
CALIXAR
CASI Pharmaceuticals
Catalent Biologics
Celgene
Celldex Therapeutics
Center for Applied Medical Research
Centrose
Checkpoint Therapeutics
China National Biotec Group
CleveXel Pharma
Columbia University Irving Medical Center
Compass Therapeutics
Compugen
Corvus Pharmaceuticals
Crescendo Biologics
CStone Pharmaceuticals
Curis
D5Pharma
Daiichi Sankyo
Distributed Bio
DNAtrix
Domain Therapeutics
Dova Pharmaceuticals
Dualogics
Eisai
Eli Lilly
Elpiscience Biopharma
ELSALYS BIOTECH
EMulate Therapeutics
EpicentRx
FF Pharmaceuticals
Five Prime Therapeutics
Forty Seven
Fred Hutchinson Cancer Research Center
F-star
Gateway Biologics
Genentech
Genmab
Genomics Medicine Ireland
Genosco
GigaGen
Gilead Sciences
Glaxosmithkline
Glenmark
Glycotope
Hanmi Pharmaceutical
HanX Biopharmaceuticals
Heat Biologics
Hrain Biotechnology
Hummingbird Bioscience
IGM Biosciences
I-Mab Biopharma
Immatics
ImmuneOncia Therapeutics
ImmuneOnco Biopharmaceuticals
ImmuNext
Impetis Biosciences
Incyte
Inhibrx
Innate Pharma
Innovent Biologics
Institute for Research in Biomedicine
InteRNA Technologies
International Myeloma Foundation
IO Biotech
iOnctura
iTeos Therapeutics
Janssen Pharmaceuticals
Jiangxi Qingfeng Pharmaceutical
JN Biosciences
Johns Hopkins University
Johnson & Johnson
Juventas Cell Therapy
KAHR Medical
Kiniksa Pharmaceuticals
Kite Pharma
Kleo Pharmaceuticals
Kymab
Kyowa Hakko Kirin
Leap Therapeutics
LG Chem
LifeArc
Lynkcell
Macrocure
MacroGenics
Marino Biotechnology
Massachusetts General Hospital
MedImmune
Merck
Merus
Moderna
Molecular Partners
Molecular Templates
Momenta Pharmaceuticals
Morphiex
MorphoSys
Mount Sinai Innovation Partners
Nanjing Chia Tai Tianqing
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute of Allergy and Infectious Diseases
National Institute of Biomedical Imaging and Bioengineering
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Neurological Disorders
NavarraBiomed-Biomedical Research Centre
Navigen
Neon Therapeutics
NewLink Genetics
NextCure
Novartis
Novimmune
Numab Therapeutics
Ogeda
OncoArendi Therapeutics
Oncotelic
Ono Pharmaceutical
ORIC Pharmaceuticals
OSE Immunotherapeutics
Palobiofarma
Pandion Therapeutics
Paradigm Shift Therapeutics
Parker Institute for Cancer Immunotherapy
Pascal Biosciences
Peloton Therapeutics
PeptiDream
PersonGen BioTherapeutics (Suzhou)
Pfizer
PharmAbcine
Pieris Pharmaceuticals
Pinze Lifetechnology
Potenza Therapeutics
PsiOxus Therapeutics
Roche
Rubius Therapeutics
Sanofi
Sanquin
Seattle Genetics
Shanghai GeneChem
Shattuck Labs
Shire
Sorrento Therapeutics
Stanford University
Surface Oncology
Sutro Biopharma
Swedish Orphan Biovitrum
Symphogen
Synthon International Holding
Syros Pharmaceuticals
Takeda Pharmaceutical
Tarus Therapeutics
Tempest Therapeutics
TESARO
TG Therapeutics
The University of Texas MD Anderson Cancer Center
Tottori University
TRACON Pharmaceuticals
Trellis Biosciences
TRIGR Therapeutics
Trillium Therapeutics
Tsinghua University
Union Stem Cell & Gene Engineering
University of California San Francisco
University of California, Los Angeles
University of California, San Diego
University of Minnesota
Vall d’Hebron Institute of Oncology
Valo Therapeutics
Viela Bio
ViraTherapeutics
Vivoryon Therapeutics
Washington University
Waterstone Hanxbio
Xencor
XOMA
Y-Biologics
Yale Cancer Center
Yale University
Y-mAbs Therapeutics
Yuhan Pharmaceuticals
Zai Lab
Zymeworks

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4787EUR$4,899USD£3,996GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7815EUR$7,999USD£6,525GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15632EUR$15,999USD£13,050GBP

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Immune Checkpoint Inhibitors Market by Type, Indication, Route of Administration, End-Users, Distribution Channel - Global Forecast 2025-2030

Immune Checkpoint Inhibitors - Market Insights, Competitive Landscape, and Market Forecast - 2030

Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report by Type (PD-1, PD-L1, CTLA-4), Application (Lung Cancer, Breast Cancer, Melanoma), Distribution Channel, Region, and Segment Forecasts, 2024-2030

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2024-2032

Immune Checkpoint Inhibitors Market Report and Forecast 2024-2032